Persistent symptomatic parvovirus B19 infection with severe thrombocytopenia transmitted by red blood cell transfusion containing low parvovirus B19 DNA levels

Transfusion

Volumn 57, Issue 6, 2017, Pages 1414-1418

  Nagaharu, Keiki ^a   Sugimoto, Yuka ^b   Hoshi, Yuji ^c   Yamaguchi, Takanori ^a   Ito, Ryugo ^a   Matsubayashi, Keiji ^c   Kawakami, Keiki ^a   Ohishi, Kohshi ^d  

^a SUZUKA GENERAL HOSPITAL   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SUWA RED CROSS HOSPITAL   (Japan)

^d MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS DNA;

ADULT; ANEMIA; ARTICLE; BLOODY DIARRHEA; BONE MARROW EXAMINATION; CASE REPORT; DIABETIC NEPHROPATHY; DISEASE SEVERITY; END STAGE RENAL DISEASE; ERYTHEMA INFECTIOSUM; ERYTHROBLAST; ERYTHROCYTE TRANSFUSION; HEMODIALYSIS; HEMORRHAGIC COLITIS; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOCOMPROMISED PATIENT; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCYTOPENIA; PYREXIA IDIOPATHICA; THROMBOCYTOPENIA; ENZYME IMMUNOASSAY; GENETICS; HUMAN PARVOVIRUS B19; PARVOVIRIDAE INFECTIONS; PATHOGENICITY; PATHOLOGY;

DNA, VIRAL; ERYTHROCYTE TRANSFUSION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; THROMBOCYTOPENIA;

EID: 85017136163     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14088     Document Type: Article

References (18)

1. Cossart YE, Field AM, Cant B, et al. Parvovirus-like particles in human sera. Lancet 1975;1:72-3.
2. Brown KE, Young NS, Alving BM, et al. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001;41:130-5.
3. Geng Y, Wu CG, Bhattacharyya SP, et al. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007;47:883-9.
4. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985;152:257-65.
5. Adams ST, Schmidt KM, Cost KM, et al. Common variable immunodeficiency presenting with persistent parvovirus B19 infection. Pediatrics 2012;130:e1711-5.
6. Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002;76:9124-34.
7. Koenigbauer, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000;40:1203-6.
8. Cassinotti P, Siegl G. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis 2000;19:886-7.
9. Kleinman SH, Glynn SA, Lee TH, et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009;114:3677-83.
10. Yu MY, Alter HJ, Virata-Theimer ML, et al. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion 2010;50:1712-21.
11. Schmidt M, Themann A, Drexler C, et al. Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007;47:1775-82.
12. Matsukura H. Posttransfusional side effect caused by human parvovirus B19 and safety measures in Japan. Jpn J Transfus Cell Ther 2014;60:561-4.
13. Satake M, Hoshi Y, Taira R, et al. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion 2011;51:1887-95.
14. Sakata H, Matsubayashi K, Takeda H, et al. Genotypic specificity of chemiluminescent enzyme immunoassay screening for human parvovirus B19 antigen in blood donors. Jpn J Transfus Cell Ther 2011;57:146-52.
15. Sakata H, Matsubayashi K, Ihara H, et al. Impact of chemiluminescent enzyme immunoassay screening for human parvovirus B19 antigen in Japanese blood donors. Transfusion 2013;53:2556-66.
16. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307-12.
17. Kelesidis T, Daikos G, Boumpas D, et al. Does rituximab increase in the incidence of infectious complications? A narrative review. Int J Infect Dis 2011;15:e2-16.
18. Marano G, Vaglio S, Pupella S, et al. Human parvovirus B19 and blood product safety: a tale of twenty years of improvements. Blood Transfus 2015;13:184-96.